Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®

@article{Magnenat2017DemonstrationOP,
  title={Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®},
  author={Laurent Magnenat and A. Palmese and C. Fr{\'e}maux and F. D'Amici and Mariagrazia Terlizzese and M. Rossi and Laurent Chevalet},
  journal={mAbs},
  year={2017},
  volume={9},
  pages={127 - 139}
}
  • Laurent Magnenat, A. Palmese, +4 authors Laurent Chevalet
  • Published 2017
  • Chemistry, Medicine
  • mAbs
  • ABSTRACT Biosimilars are biological products that are highly similar to existing products approved by health authorities. Demonstration of similarity starts with the comprehensive analysis of the reference product and its proposed biosimilar at the physicochemical and functional levels. Here, we report the results of a comparative analysis of a proposed biosimilar adalimumab MSB11022 and its reference product, Humira®. Three batches of MSB11022 and up to 23 batches of Humira® were analyzed by a… CONTINUE READING
    26 Citations
    Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review.
    Biosimilars in Dermatology – theory becomes reality
    • 7

    References

    SHOWING 1-10 OF 35 REFERENCES
    Physicochemical characterization of Remsima®
    • 301
    • PDF
    Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira® in healthy subjects
    • 24
    A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults
    • 167
    • PDF
    Biosimilars: the science of extrapolation.
    • 228
    • PDF
    Biosimilars: what clinicians should know.
    • 283
    • PDF
    A broad range of Fab stabilities within a host of therapeutic IgGs.
    • 178
    Acceptable changes in quality attributes of glycosylated biopharmaceuticals
    • 400